Intas Pharmaceuticals Limited — Chloroquine Exporter Profile
Indian Pharmaceutical Exporter · #5 for Chloroquine · $1.1M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #5 Indian exporter of Chloroquine with $1.1M in export value and 21 verified shipments. Intas Pharmaceuticals Limited holds a 0.6% market share in Chloroquine exports across 3 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Chloroquine Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Chloroquine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $720.8K | 19 | 91.5% |
| CHILE | $50.0K | 1 | 6.4% |
| CANADA | $16.6K | 1 | 2.1% |
Intas Pharmaceuticals Limited exports Chloroquine to 3 countries. The largest destination is UNITED STATES accounting for 91.5% of Intas Pharmaceuticals Limited's Chloroquine shipments, followed by CHILE (6.4%) and CANADA (2.1%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Chloroquine from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EVERSANA LIFE SCIENCES SERVICES,LLC | UNITED STATES | $574.0K | 15 |
| EVERSANA LIFE SCIENCES SERVICES LLC | UNITED STATES | $146.7K | 4 |
| TO THE ORDER | CHILE | $50.0K | 1 |
| NORA PHARMA INC | CANADA | $16.6K | 1 |
Intas Pharmaceuticals Limited supplies Chloroquine to 4 buyers globally. The largest buyer is EVERSANA LIFE SCIENCES SERVICES,LLC (UNITED STATES), followed by EVERSANA LIFE SCIENCES SERVICES LLC (UNITED STATES) and TO THE ORDER (CHILE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Chloroquine Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $40.7M worth of Chloroquine through 5,437 shipments from 287 suppliers to 120 countries, serving 774 buyers globally. Intas Pharmaceuticals Limited contributes $1.1M to this total, accounting for 0.6% of India's Chloroquine exports. Intas Pharmaceuticals Limited ships Chloroquine to 3 countries through 4 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Chloroquine Exports?
Intas Pharmaceuticals Limited's average Chloroquine shipment value is $50.0K per consignment, based on 21 shipments totaling $1.1M. The largest destination is UNITED STATES (91.5% of Intas Pharmaceuticals Limited's Chloroquine exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Chloroquine Exporters?
Intas Pharmaceuticals Limited ranks #5 among 287 Indian Chloroquine exporters with a 0.6% market share. The top 3 exporters are IPCA LABORATORIES LIMITED ($19.1M), ZYDUS LIFESCIENCES LIMITED ($13.0M), CADILA HEALTHCARE LIMITED ($2.0M). Intas Pharmaceuticals Limited processed 21 shipments to 3 destination countries.
What Chloroquine Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHR DRUGS & MEDI HYDROXYCHLOROQUINE USP | $250.0K | 5 |
| PHARMA DRUGS & MEDI HYDROXYCHLOROQUINE U | $177.1K | 6 |
| PHARMA DRUGS & MEDI HYDROXYCHLOROQUINE USP 200MG 500T(AC-US AS PER INVOICE | $96.9K | 3 |
| PHARMA DRUGS & MEDI HYDROXYCHLOROQUINE USP 200MG 500TAC-US AS PER DOCUMENT | $96.7K | 3 |
| PHARMA DRUGS & MEDI HYDROXYCHLOROQUINE USP 200MG 100TAC-US AS PER DOCUMENT | $50.0K | 1 |
| PHARMA DRUGS & MEDI HYDROXYCHLOROQUINE USP 200MG 100T(AC-US AS PER INVOICE | $50.0K | 1 |
| PHARM DRUG&MED:ILINOL HIDROXICLO SUL 200MG 3X10T MEG-CL EACH COATED TABLET CONTHYDROXYCHLOROQUINE SULFATE 200 MG EXCIPI | $50.0K | 1 |
| PHARMA DRUGS AND MEDI PR NRA HYDROXYCHLOROQUINE 200 100T CAN AS PER INV | $16.6K | 1 |
Intas Pharmaceuticals Limited exports 8 distinct Chloroquine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHR DRUGS & MEDI HYDROXYCHLOROQUINE USP with 5 shipments worth $250.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Chloroquine to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Chloroquine to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Chloroquine Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | ZYDUS LIFESCIENCES LIMITED | $13.0M | 260 | 8 | $50.0K |
| 3 | CADILA HEALTHCARE LIMITED | $2.0M | 41 | 5 | $50.0K |
| 5 | INTAS PHARMACEUTICALS LIMITED ★ | $1.1M | 21 | 3 | $50.0K |
| 7 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED | $950.0K | 19 | 2 | $50.0K |
| 8 | NITIN LIFESCIENCES LIMITED | $854.3K | 50 | 1 | $17.1K |
Intas Pharmaceuticals Limited ranks #5 among 287 Indian Chloroquine exporters. Average shipment value of $50.0K compared to the market average of $141.7K. The closest competitors by value are ZYDUS LIFESCIENCES LIMITED and CADILA HEALTHCARE LIMITED.
Which Indian Ports Ship Chloroquine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 1,431 | 26.3% |
| SAHAR AIR | 1,199 | 22.1% |
| DELHI AIR CARGO ACC (INDEL4) | 657 | 12.1% |
| Bombay Air | 359 | 6.6% |
| DELHI AIR | 325 | 6.0% |
| MUNDRA SEA | 156 | 2.9% |
| NHAVA SHEVA SEA (INNSA1) | 136 | 2.5% |
| Delhi Air | 127 | 2.3% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Chloroquine Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Chloroquine, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Chloroquine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Chloroquine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 21 individual customs records matching Intas Pharmaceuticals Limited exporting Chloroquine, covering 8 formulations to 3 countries via 4 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 120+ countries, 774+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Chloroquine Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Chloroquine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Chloroquine Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Chloroquine. For current shipment-level data, contact TransData Nexus.